Originally published as JCO Early Release 10.1200/JCO.2007.11.9453 on August 6 2007
Journal of Clinical Oncology, Vol 25, No 25 (September 1), 2007: pp. 3846-3852
© 2007 American Society of Clinical Oncology.
Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98
Giuseppe Viale,
Meredith M. Regan,
Eugenio Maiorano,
Mauro G. Mastropasqua,
Patrizia Dell'Orto,
Birgitte Bruun Rasmussen,
Johnny Raffoul,
Patrick Neven,
Zsolt Orosz,
Stephen Braye,
Christian Öhlschlegel,
Beat Thürlimann,
Richard D. Gelber,
Monica Castiglione-Gertsch,
Karen N. Price,
Aron Goldhirsch,
Barry A. Gusterson,
Alan S. Coates
From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA; Department of Pathological Anatomy, University of Bari, Bari, Italy; Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy; Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy; Department of Pathology, Nordsjaellands Hospital, Hilleroed, Denmark; Service d'Anatomie et de Cytologie Pathologiques, Centre Hospitalier-site-Belfort-Montbéliard, Montbéliard, France; Department of Gyn Oncol and Multidisciplinary Breast Centre, UZ-KULeuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New Lambton Heights, NSW, Australia; Kantonsspital, St Gallen, Swiss Group for Clinical Cancer Research, Bern, Switzerland; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen, Switzerland, Swiss Group for Clinical Cancer Research; IBCSG Statistical Center, Dana-Farber Cancer Institute, Frontier Science and Technology Research Foundation, Harvard School of Public Health, Boston, MA; IBCSG Coordinating Center, Bern, Switzerland; IBCSG Statistical Center and Frontier Science and Technology Research Foundation, Boston, MA; European Institute of Oncology, Milan, Italy; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Division of Cancer Sciences and Molecular Pathology, Western Infirmary, University of Glasgow, UK; International Breast Cancer Study Group, Bern, Switzerland and University of Sydney, Australia
Address reprint requests to Giuseppe Viale, MD, FRCPath, Divisione di Anatomia Patologica e Medicina di Laboratorio, Istituto Europeo di Oncologia, Via Ripamonti, 435, 20141 Milano, Italy; e-mail: giuseppe.viale{at}ieo.it
Purpose To evaluate locally versus centrally assessed estrogen (ER) and progesterone (PgR) receptor status and the impact of PgR on letrozole adjuvant therapy compared with tamoxifen in postmenopausal women with early breast cancer.
Patients and Methods Breast International Group (BIG) 1-98 randomly assigned 8,010 patients to four arms comparing letrozole and tamoxifen with sequences of each agent. The Central Pathology Office received material for 6,549 patients (82%), of which 79% were assessable (6,291 patients). Prognostic and predictive value of both local and central hormone receptor expression on disease-free survival (DFS) were evaluated among 3,650 assessable patients assigned to the monotherapy arms. Prognostic value and the treatment effect were estimated for centrally assessed ER and PgR expression levels using the Subpopulation Treatment Effect Pattern Plot.
Results Central review confirmed 97% of tumors as hormone receptor–positive (ER and/or PgR 10%). Of 105 tumors locally ER-negative, 73 were found to have more than 10% positive cells, and eight had 1% to 9%. Of 6,100 tumors locally ER positive, 66 were found to have no staining, and 54 had only 1% to 9%. Discordance was more marked for PgR than ER. Patients with tumors reclassified centrally as ER-negative, or as hormone receptor–negative, had poor DFS. Centrally assessed ER and PgR showed prognostic value. Among patients with centrally assessed ER-expressing tumors, letrozole showed better DFS than tamoxifen, irrespective of PgR expression level.
Conclusion Central review changed the assessment of receptor status in a substantial proportion of patients, and should be performed whenever possible in similar trials. PgR expression did not affect the relative efficacy of letrozole over tamoxifen.
published online ahead of print at www.jco.org on August 6, 2007.
Presented in part at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-11, 2005.
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. J. Howell, A. M. Wardley, and A. C. Armstrong
Re: Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
J Natl Cancer Inst,
November 5, 2009;
(2009)
djp390v1.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Castorina, D. Carco, C. Guiot, and T. S. Deisboeck
Tumor Growth Instability and Its Implications for Chemotherapy
Cancer Res.,
November 1, 2009;
69(21):
8507 - 8515.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Decensi, C. Robertson, A. Guerrieri-Gonzaga, D. Serrano, M. Cazzaniga, S. Mora, M. Gulisano, H. Johansson, V. Galimberti, E. Cassano, et al.
Randomized Double-Blind 2 x 2 Trial of Low-Dose Tamoxifen and Fenretinide for Breast Cancer Prevention in High-Risk Premenopausal Women
J. Clin. Oncol.,
August 10, 2009;
27(23):
3749 - 3756.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Bueno-de-Mesquita, D. S. A. Nuyten, J. Wesseling, H. van Tinteren, S. C. Linn, and M. J. van de Vijver
The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment
Ann. Onc.,
July 21, 2009;
(2009)
mdp273v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Giobbie-Hurder, K. N Price, and R. D Gelber
Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer
Clinical Trials,
June 1, 2009;
6(3):
272 - 287.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Merglen, H. M. Verkooijen, G. Fioretta, I. Neyroud-Caspar, V. Vinh-Hung, G. Vlastos, P. O. Chappuis, M. Castiglione, E. Rapiti, and C. Bouchardy
Hormonal therapy for oestrogen receptor-negative breast cancer is associated with higher disease-specific mortality
Ann. Onc.,
May 1, 2009;
20(5):
857 - 861.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. A. Iverson, C. Gillett, P. Cane, C. D. Santini, T. M. Vess, L. Kam-Morgan, A. Wang, M. Eisenberg, C. M. Rowland, J. J. Hessling, et al.
A Single-Tube Quantitative Assay for mRNA Levels of Hormonal and Growth Factor Receptors in Breast Cancer Specimens
J. Mol. Diagn.,
March 1, 2009;
11(2):
117 - 130.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Dowsett and A. K. Dunbier
Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer
Clin. Cancer Res.,
December 15, 2008;
14(24):
8019 - 8026.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Viale, A. Giobbie-Hurder, M. M. Regan, A. S. Coates, M. G. Mastropasqua, P. Dell'Orto, E. Maiorano, G. MacGrogan, S. G. Braye, C. Ohlschlegel, et al.
Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole
J. Clin. Oncol.,
December 1, 2008;
26(34):
5569 - 5575.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. C. Allred
Commentary: Hormone Receptor Testing in Breast Cancer: A Distress Signal from Canada
Oncologist,
November 1, 2008;
13(11):
1134 - 1136.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R A Walker
Immunohistochemical markers as predictive tools for breast cancer
J. Clin. Pathol.,
June 1, 2008;
61(6):
689 - 696.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Ponzone, P. Mininanni, E. Cassina, F. Pastorino, and P. Sismondi
Aromatase inhibitors for breast cancer: different structures, same effects?
Endocr. Relat. Cancer,
March 1, 2008;
15(1):
27 - 36.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Parton and I. E. Smith
Controversies in the Management of Patients With Breast Cancer: Adjuvant Endocrine Therapy in Premenopausal Women
J. Clin. Oncol.,
February 10, 2008;
26(5):
745 - 752.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. U. Lin and E. P. Winer
Advances in Adjuvant Endocrine Therapy for Postmenopausal Women
J. Clin. Oncol.,
February 10, 2008;
26(5):
798 - 805.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. A. Rakha and I. O. Ellis
In Reply
J. Clin. Oncol.,
January 10, 2008;
26(2):
336 - 338.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Aebi and M. Rabaglio
Overview of Current Approaches to Adjuvant Endocrine Therapy
ASCO Educational Book,
January 1, 2008;
2008(1):
9 - 13.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Dowsett
Factors Predicting Response and Resistance to Endocrine Therapy of Breast Cancer
ASCO Educational Book,
January 1, 2008;
2008(1):
14 - 17.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|